EXOSOMM

Bioactive Milk Exosome Ingredients for Medical Foods and Inflammation

Health Tech & Life Sciences
Active
Seed Haifa, Israel Founded 2021
Last updated 2026-06-18
Total raised
$4.5M
Last: Grant 2025-03
Stage
Seed
Founded
2021
Headcount
9
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences

About

Exosomm develops bioactive nutritional ingredients based on natural milk exosomes for the medical food and nutraceutical sectors. The company utilizes a patented, chemical-free technology to isolate these natural nanoparticles from whey, a byproduct of the cheese-making industry, ensuring the preservation of their active cargo. These milk-derived exosomes function as durable biological carriers for microRNAs, which naturally regulate immune responses and facilitate targeted intercellular communication.

The company’s flagship solution targets Inflammatory Bowel Diseases (IBD), such as Crohn's and Colitis, providing a non-synthetic method to reduce inflammation scores and extend remission periods. By upcycling dairy industry byproducts, the platform delivers a sustainable and scalable source of functional ingredients with high bioavailability and stability. This approach offers a clinically validated, food-based alternative for managing chronic inflammatory and metabolic disorders without the adverse effects often associated with traditional pharmaceutical treatments.

Funding history · 6 rounds · $4.5M total

2025-03
Grant $1.5M
2024-03
Grant $80K
2023-03
Grant $420K
2021-12
2021-12

Q&A

What is EXOSOMM's primary focus?
EXOSOMM develops bioactive nutritional ingredients based on natural milk exosomes for the medical food and nutraceutical sectors, with a flagship solution targeting Inflammatory Bowel Diseases (IBD).
When was EXOSOMM founded?
EXOSOMM was founded in December 2021.
What is EXOSOMM's total funding to date?
EXOSOMM has raised a total of $4,520,000 USD.
When did EXOSOMM receive its most recent funding?
EXOSOMM received a Grant of $1,500,000 USD in March 2025.
Which investors participated in EXOSOMM's January 2025 funding round?
In January 2025, EXOSOMM received funding from Tnuva Ventures and Siddhi Capital.
What technology does EXOSOMM utilize for its ingredients?
EXOSOMM uses a patented, chemical-free technology to isolate natural nanoparticles from whey, a byproduct of the cheese-making industry.
What is EXOSOMM's current product stage?
EXOSOMM's product is currently in the clinical trial stage.

Team · 4

Founder · CMO & Co-founder
LinkedIn ↗
Founder · Co-Founder & CMO
Founder · Co-founder & COO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Agriculture & Food TechnologiesFood TechNovel Food & IngredientsHealth Tech & Life SciencesPharma & Medical Biotechnology
Technologies
BiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyCosmeticsHealthcarePatientsProvidersMedical Devices IndustryMedical ProductsFood Retail & ConsumptionWholesaleAgriculture & FoodProcessed FoodsBeveragesIngredientsConsumers
Business model
B2B2CB2B

Highlights

1 PatentsVerified

Tags

novel-ingredientsmedical-productsanti-inflammatorybiotechnologyprecision-medicinehealthcaredermatologyfood-additivesbiomedfood-ingredientsinflammatory-diseasescosmeticsnatural-active-ingredientsfood-industrycosmetic-companiesdairy-farmsfoodtechwellnesspopulation-health-managementnutrition
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)